Pfizer is continuing to develop a once-daily version of its experimental weight loss pill danuglipron after seeing encouraging data from an early-stage trial testing multiple doses. The company plans to conduct more early-stage studies in the second half of 2024 to identify the optimal dose of the once-daily pill, with results expected in Q1 2025. Pfizer discontinued a twice-daily version of the drug after patients had trouble tolerating it in a mid-stage trial in late 2023. Danuglipron works similarly to approved GLP-1 drugs like Wegovy by mimicking the GLP-1 hormone to signal fullness to the brain.
Category
🗞
NewsTranscript
00:00It's Benzinga, and here's what's on the block.
00:02Pfizer is continuing to develop a once-daily version of its experimental weight loss pill
00:07after seeing encouraging data from an early-stage trial testing multiple doses.
00:12The company plans to conduct more early-stage studies in the second half of 2024 to identify
00:17the optimal dose of the once-daily pill, with results expected in Q1 2025.
00:22Pfizer previously discontinued a twice-daily version of the drug after patients had trouble
00:27tolerating it in a mid-stage trial in late 2023.
00:31The drug works similarly to approved GLP-1 drugs like WeGovie by mimicking the GLP-1
00:36hormone to signal fullness to the brain.
00:38For all things money, visit Benzinga.com.